Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) EPS (Basic) (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EPS (Basic) for 4 consecutive years, with -$0.38 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) rose 7.32% to -$0.38 in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.8, a 11.8% decrease, with the full-year FY2024 number at -$1.66, down 12.16% from a year prior.
  • EPS (Basic) was -$0.38 for Q3 2025 at Orchestra BioMed Holdings, up from -$0.5 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of -$0.12 in Q2 2022 to a low of -$2.14 in Q4 2022.
  • A 4-year average of -$0.53 and a median of -$0.41 in 2024 define the central range for EPS (Basic).
  • Biggest YoY gain for EPS (Basic) was 82.71% in 2023; the steepest drop was 191.67% in 2023.
  • Orchestra BioMed Holdings' EPS (Basic) stood at -$2.14 in 2022, then skyrocketed by 82.71% to -$0.37 in 2023, then dropped by 16.22% to -$0.43 in 2024, then grew by 11.63% to -$0.38 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's EPS (Basic) are -$0.38 (Q3 2025), -$0.5 (Q2 2025), and -$0.49 (Q1 2025).